Introduction {#Sec1}
============

Infantile spasms (IS; West syndrome) is a rare (occurring in about 1.6--4.5/10,000 live births) \[[@CR1]--[@CR4]\], but often devastating form of epilepsy that typically occurs in the first year of life \[[@CR2]\]. Although spasms usually resolve by age five, the long-term prognoses of infants diagnosed with IS are relatively poor, with the majority of patients developing conditions, such as refractory epilepsy, mental retardation, and autistic spectrum disorders \[[@CR2], [@CR5]--[@CR9]\]. While the therapeutic response and complete resolution of IS largely depend on the underlying etiology and other clinical factors, early diagnosis and prompt treatment may improve neurological and developmental outcomes \[[@CR2], [@CR9], [@CR10]\].

In the US, hormonal therapies, such as intramuscular adrenocorticotropic hormone (ACTH), are commonly used to treat IS; a recent survey of clinicians treating IS reported that 84% prescribed ACTH \[[@CR11]\]. However, only two drugs have received US Food and Drug Administration (FDA) approval to treat IS: the gamma-aminobutyric acid transaminase inhibitor vigabatrin (Sabril^®^; Lundbeck) \[[@CR12]\] and H.P. Acthar^®^ Gel (repository corticotropin injection; Acthar; Mallinckrodt) \[[@CR13]\]. Following treatment, infants typically undergo electroencephalograms (EEGs) to evaluate treatment effectiveness, which is defined as both complete cessation of spasms as well as the resolution of hypsarrhythmia on EEGs \[[@CR2]\] and, if indicated, treatments are modified \[[@CR5]\].

Although analysis of healthcare resource utilization in patients with convulsive disorders is the starting point for economic assessment of the medical burden of these conditions, little research has been conducted. The purpose of this study was to describe health outcomes and costs resulting from early (within 30 days of diagnosis) prescriptions of Acthar versus later (more than 30 days after diagnosis) prescriptions to generate hypotheses for future studies on healthcare utilization and treatment patterns among patients with IS.

Methods {#Sec2}
=======

Study Population and Data Source {#Sec3}
--------------------------------

We used the Truven Health MarketScan^®^ Commercial Claims and Encounters Database and the Truven Health MarketScan Multi-State Medicaid Database to identify the study cohort. These databases contained inpatient, outpatient, pharmacy claims, and insurance coverage data for patients across the US who are enrolled in commercial insurance plans. The inpatient and outpatient claims databases include procedure and visit-level details from medical claims, such as the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, Current Procedural Terminology (CPT) medical procedure codes, dates of service, and variables describing financial expenditures. The pharmacy claims database provided details, including National Drug Codes (NDC), dates dispensed, quantity and days' supply, and payments made for each claim. A separate eligibility and demographics file provided additional information about each subject, such as age, gender, insurance plan type, geographic location, and enrollment status by month.

We included patients in the MarketScan Research Database who received treatment for IS (ICD-9-CM diagnosis code: 345.60) between April 1, 2007 and December 31, 2012 who were less than 2 years old at the time of the IS diagnosis. This age restriction is aligned with the US FDA's labeled indication for Acthar \[[@CR14]\]. Patients with subsequent diagnoses of tuberous sclerosis complex (TSC; ICD-9-CM diagnosis code: 759.5) were excluded from our analyses. TSC is a complex genetic disorder that can affect multiple organs and is usually treated effectively with vigabatrin or surgery \[[@CR15]\]. To have complete comorbidity and health outcome data, we also excluded patients who were not enrolled in their health plans continuously for at least 3 months prior and 12 months after the index date.

We classified patients in our study cohort who had outpatient prescriptions or procedure codes indicating the receipt of prescriptions for Acthar (NDCs: 63004-77310-1, 63004-87100-1; CPT code: J0800) into those who received Acthar prescriptions early (within 30 days of the index IS incident) and those who received Acthar prescriptions later (more than 30 days after the index IS incident). Patients who received prescriptions for Acthar within 30 days and, in addition, received prescriptions for Acthar more than 30 days after their index diagnoses were included in the early Acthar group. We assumed the subsequent prescriptions for Acthar were likely to be continuations of therapies that began within 30 days.

The MarketScan Research Database contained patient demographic variables, including age, gender, type of health insurance plan (types of private plans and Medicaid versus non-Medicaid), and geographic region (although region data were not available for patients with Medicaid). We also assessed year of IS diagnosis and the number of outpatient services, hospitalizations, and medications filled in the 90 days prior to index IS incident. In addition, we also looked for use of anticonvulsants, steroids, or vigabatrin (Sabril) prior to receipt of Acthar prescriptions (see Table S1 in the supplementary material for a complete list of these medications), previous diagnoses of major cardiac diseases, central nervous system malformations, and severe metabolic conditions (see Table S2 in the supplementary material for a complete list of the ICD-9-CM diagnosis codes included in each of these categories).

Statistical Analysis {#Sec4}
--------------------

We calculated proportions and Chi-square tests (for categorical variables) and means, standard deviations, and *t* tests (for continuous variables) of factors that might have been related to health costs and outcomes and early receipt of Acthar prescriptions. Variables with *P* values of ≤0.05 were considered significant confounders. Next, we calculated means, medians, ranges, standard deviations, and differences between means of each healthcare utilization and cost among patients who received early Acthar prescriptions compared to patients who received late Acthar prescriptions. Because we made multiple comparisons (*n* = 15), we determined that *P* values of 0.01 would represent statistically significant associations between receipt of early Acthar prescriptions and each utilization or cost outcome. We calculated adjusted means and adjusted differences between means. For outcomes with count variables, we used generalized linear regression with log links and specified the Poisson distribution to calculate adjusted means and 99% confidence intervals (CIs). For the binary outcome of whether patients were readmitted to the hospital within 30 days of discharge, we used logistic regression to calculate odds ratios (ORs) and 99% CIs. For cost outcomes, we used generalized linear regressions with log links and specified the gamma distribution to calculate adjusted means and 99% CIs. To allow cost models to run, nominal amounts were added to patients with zero costs. Because the inclusion of covariates in the adjusted models affected the estimates of component costs, individual cost components did not add exactly to the adjusted total costs.

SAS for Windows, version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.

Compliance with Ethics Guidelines {#Sec100}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, revised in 2013. This study was exempt from review by the University of Washington Institutional Review Board (IRB) through self-determination.

Results {#Sec6}
=======

Out of 108,860,485 individuals enrolled in the MarketScan and Medicaid databases between April 1, 2007 and December 31, 2012, a total of 5158 patients with IS were identified (Fig. [1](#Fig1){ref-type="fig"}). Of these, 201 patients were excluded, because they had subsequent diagnoses of tuberous sclerosis, and 1949 patients were excluded, because they were not enrolled for at least 3 months before and 12 months after their initial IS diagnoses. We also excluded 2000 patients, because their ages were missing or they were not less than 2 years old at the time of their IS diagnoses. Of the remaining 1008 patients, 756 were excluded, because they did not receive prescriptions for Acthar. Of the 252 patients with IS who received prescriptions for Acthar, 191 (76%) were prescribed Acthar within 30 days or less.Fig. 1Study participant flow

Demographic characteristics of patients who received prescriptions for Acthar are shown in Table [1](#Tab1){ref-type="table"}. A smaller proportion of early Acthar prescription recipients were female compared to male (39% versus 61%; *P* = 0.03). A higher proportion of patients who received Acthar later filled prescriptions for anticonvulsants prior to filling prescriptions for Acthar (21% versus 33%; *P* = 0.07). In addition, higher proportions of patients who received Acthar later had been diagnosed with severe central nervous system malformations prior to being diagnosed with IS (14% versus 31%; *P* = 0.002). Patients who were prescribed Acthar early had fewer hospitalizations in the 90 days prior to the IS diagnosis compared to patients who were prescribed Acthar later (0.2 versus 0.6; *P* = 0.0002). Patients who were prescribed Acthar early were similar to those who were prescribed Acthar later in terms of age, insurance plan, geographic region, and year of IS diagnosis, whether they filled prescriptions for steroids prior to filling prescriptions for Acthar, whether they had diagnoses of major cardiac diseases or metabolic conditions, and the number of outpatient services and medications in the 90 days prior to diagnosis. No patients received vigabatrin prior to receiving prescriptions for Acthar.Table 1Characteristics of infantile spasm patients prescribed Acthar within 30 days of index diagnosis compared to patients prescribed Acthar more than 30 days after diagnosisCharacteristicsActhar Rx^a^ (≤30 days post-index) *n* = 191 (76%)Acthar Rx^a^ (\>30 days post-index) *n* = 61 (24%)*P* value^b^Age (years), mean (SD)0.62 (0.49)0.64 (0.48)0.76Age 0 to \< 1 year73 (38%)22 (36%)0.76Age 1 to \< 2 years118 (62%)39 (64%)Female74 (39%)33 (54%)0.03Male117 (61%)28 (46%)Non-Medicaid154 (81%)49 (80%)0.96Medicaid37 (19%)12 (20%)Type of health plan Comprehensive18 (9%)9 (15%)0.42 Exclusive/preferred provider organization93 (49%)32 (52%) Health maintenance organization46 (24%)9 (15%) Point of service19 (10%)7 (11%) Consumer-directed/high-deductible15 (8%)3 (5%) Missing0 (0.0%)1 (1%)Geographic region Northeast27 (14%)9 (15%)0.82 North Central46 (24%)13 (21%) South51 (27%)16 (26%) West25 (13%)11 (18%) Missing^c^42 (22%)12 (20%)Year of IS incident 200729 (15%)7 (11%)0.19 200835 (18%)21 (34%) 200934 (18%)8 (13%) 201035 (18%)11 (18%) 201130 (16%)8 (13%) 201228 (15%)6 (10%)Rx filled prior to IS diagnosis^d^ Steroid11 (6%)6 (10%)0.27 Anticonvulsant41 (21%)20 (33%)0.07 Vigabatrin0 (0.0%)0 (0.0%)--Comorbidities diagnosed prior to IS diagnosis^e^ Major cardiac diseases43 (23%)19 (31%)0.17 Metabolic conditions17 (9%)6 (10%)0.83 Severe central nervous system malformations26 (14%)19 (31%)0.002Number of utilizations from days −90 to −1, mean ± SD (range) Outpatient services10.2 ± 9.6 (0--54)12.5 ± 9.5 (1--38)0.12 Hospital admissions0.2 ± 0.5 (0--2)0.6 ± 1.0 (0--4)0.0002 Medications3.5 ± 4.9 (0--31)4.0 ± 4.4 (0--19)0.54*Rx* prescription, *SD* standard deviationValues are given as *n* (%) unless otherwise stated^a^Patients could have had both early and late Acthar Rx (*n* = 63)^b^ *P* value calculated using *t* test for continuous variables or Chi-square test for categorical variables^c^Region data missing from patients in Medicaid database^d^See Table S1 for list of National Drug Codes and generic names of each type of medication^e^See Table S2 for list of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes of each type of comorbidity

In unadjusted analyses (Table [2](#Tab2){ref-type="table"}), we found that patients who were prescribed Acthar within 30 days of diagnosis had non-statistically significantly reduced outpatient services (12 fewer procedures; 99% CI −29 to 3.7), fewer inpatient, outpatient, and medication fills combined (18 fewer health services; 99% CI −40 to 3.9), and similar costs. The two groups were similar in terms of number of hospitalizations, mean length of stay per hospitalization, number of admissions to the intensive care unit, readmissions within 30 days, emergency room visits, hospitalization costs, and total costs. Following adjustment for gender, comorbid diagnoses of central nervous system disorders, and hospitalizations in the 90 days prior to the IS diagnosis (Table [3](#Tab3){ref-type="table"}), the association between early Acthar prescriptions and the number of outpatient services became statistically significant (3.8 fewer outpatient procedures; 99% CI −6.7 to −0.7) as did the reduced number of total health services (4.2 fewer total health services; 99% CI −7.9 to −0.4). We also found that, among patients who had at least one hospitalization, those who received Acthar early were almost twice as likely to have been readmitted within 30 days, though not statistically significantly (99% CI 0.7 to 5.0).Table 2Unadjusted 12-month outcomes among patients who were prescribed Acthar within 30 days of IS diagnosis compared to those who were prescribed Acthar more than 30 days after diagnosis12-month outcomeEarly Acthar Rx (≤30 days post-index), mean (median) ± SDLate Acthar Rx (\>30 days post-index), mean (median) ± SDDifference in means (99% CI)*P* valueNumber of hospitalizations2.2 (2.0) ± 1.92.4 (2.0) ± 2.0−0.2 (−0.9, 0.6)0.55Mean length of stay (days)^a^4.2 (3.0) ± 4.34.3 (3.0) ± 4.9−0.1 (−1.9, 1.7)0.88Number of ICU admissions^a^0.3 (0) ± 0.70.5 (0) ± 1.5−0.2 (−0.6, 0.2)0.26Number of ER visits1.0 (0) ± 1.71.1 (1.0) ± 1.5−0.1 (−0.7, 0.6)0.83Number of IS-related ER visits^a^0.2 (0) ± 0.50.2 (0) ± 0.50 (−0.3, 0.3)0.95Number of outpatient services62 (49) ± 4374 (65) ± 42−12 (−29, 3.7)0.05Number of Rx medication fills30.5 (27) ± 2235.9 (26) ± 23−5.4 (−14, 3.2)0.10Number of all health services combined94 (82) ± 57112 (110) ± 58−18 (−40, 3.9)0.03Total hospitalization costs (\$)72,100 (21,000) ± 170,00076,300 (17,100) ± 152,000−4200 (−68,000, 59,000)0.86Total outpatient costs (\$)38,100 (17,200) ± 58,30044,700 (21,900) ± 69,900−6600 (−30,000, 17,000)0.46Total medication costs (\$)93,100 (84,300) ± 81,30088,300 (79,800) ± 76,4004800 (−26,000, 35,000)0.68Total cost of services (\$)203,300 (149,000) ± 204,000209,300 (146,000) ± 199,000−6000 (−83,000, 71,000)0.8412-month outcomeFrequency (%) among patients receiving early Acthar Rx\* (≤30 days post-index)Frequency (%) among patients receiving late Acthar Rx\* (\>30 days post-index)Odds ratio (99% CI)*P* valueReadmissions within 30 days (yes/no)^a^59 (31%)14 (23%)1.5 (0.6, 3.6)0.24*CI* confidence interval, *ER* emergency room, *ICU* intensive care unit, *IS* Infantile spasms, *Rx* prescription, *SD* standard deviation^a^Mean length of stay, number of ICU admissions, and whether patients had any readmissions within 30 days calculated only among patients with at least one hospitalization; IS-related ER visits calculated only among people with at least 1 ER visitTable 3Multivariate regression estimates among patients who were prescribed Acthar within 30 days of infantile spasms diagnosis compared to those who were prescribed Acthar more than 30 days after diagnosisAdjusted mean (99% CI) for patients receiving Acthar Rx early^a^Adjusted mean (99% CI) for patients receiving Acthar Rx late^a^Adjusted difference in means (99% CI)^a^*P* valueNumber of hospitalizations2.3 (2.0, 2.6)2.2 (1.7, 2.7)0.1 (−0.4, 0.8)0.77Mean length of stay (days)^b^4.2 (3.8, 4.6)4.2 (3.6, 5.1)0 (−0.8, 1.0)0.88Number of ICU admissions^b^0.3 (0.2, 0.4)0.3 (0.2, 0.6)0 (−0.1, 0.4)0.90Number of ER visits1.0 (0.9, 1.3)0.9 (0.6, 1.2)0.1 (−0.1, 0.7)0.24Number of IS-related ER visits^b^0.2 (0.1, 0.4)0.2 (0.1, 0.5)0 (−0.1, 0.8)0.53Number of outpatient services62 (60, 63)65 (63, 68)−3.8 (−6.7, −0.7)0.002Number of prescription medication fills31 (30, 32)31 (29, 33)−0.4 (−2.5, 1.8)0.60Number of all health services combined95 (93, 97)99 (96, 102)−4.2 (−7.9, −0.4)0.005Total hospitalization costs (\$)^c^69,800 (50,000, 98,000)79,500 (41,000, 155,000)−9700 (−69,000, 50,000)0.67Total outpatient costs (\$)^c^37,900 (31,000, 46,000)39,000 (27,000, 57,000)−1100 (−18,000, 16,000)0.87Total medication costs (\$)^c^93,100 (70,000, 124,000)87,200 (51,000, 148,000)5900 (−50,000, 62,000)0.79Total cost of services (\$)203,000 (173,000, 238,000)201,900 (150,000, 272,000)1100 (−70,000, 72,000)0.97Adjusted mean (99% CI) for patients receiving Acthar early^a^Adjusted mean (99% CI) for patients receiving Acthar late^a^Adjusted odds ratio (99% CI)^a^*P* valueReadmissions within 30 days (yes/no)^b^0.4 (0.3, 0.4)0.2 (0.1, 0.4)1.9 (0.7, 5.0)0.09*CI* confidence interval, *ER* emergency room, *ICU* intensive care unit, *IS* Infantile spasms, *Rx* prescription, *SD* standard deviation^a^Adjusted for gender, presence of severe central nervous system malformations, total hospitalizations in prior 3 months^b^Mean length of stay, ICU admissions and readmissions within 30 days calculated only among patients with at least one hospitalization; IS-related ER visits calculated only among people with at least 1 ER visit^c^Nominal values added to patients with zero hospitalization, outpatient, or medication costs to allow model to run

Discussion {#Sec7}
==========

The majority of the patients with IS in our cohort were prescribed Acthar within 30 days of their IS diagnoses. Relative to patients who were prescribed Acthar more than 30 days after diagnosis, the patients prescribed Acthar earlier had fewer outpatient procedures performed. In spite of this reduction in utilization, total costs were similar between the two groups, possibly because the group that received Acthar early had similar numbers of expensive utilizations, such as emergency department visits and inpatient stays. The fact that we observed a two-fold increase in the odds of 30-day readmissions among patients who received Acthar earlier supports this hypothesis.

Although associations between the timing of IS treatment and healthcare utilization and costs have not been well studied, previous research has shown that earlier treatment is associated with improved developmental outcomes \[[@CR10]\]. One study showed that earlier treatment for IS significantly improved patients' Vineland Adaptive Behavior Scale (VABS) scores, which measured patients' ability to cope with environmental changes, demonstrate independence, and learn new skills \[[@CR16]\]. Another study indicated that neurodevelopmental outcomes are better for infants who have shorter duration of spasms and, therefore, shorter times of epileptic encephalopathy \[[@CR17]\]. Our study contributes to evidence that earlier treatment for IS may also be beneficial to achieve less healthcare utilization and lower medication burden.

This study had several limitations. First, exposure to Acthar was predominantly identified through outpatient prescription fills, thus it is possible that some patients were subject to misclassification, because the medication was not actually administered. However, given that Acthar is a brand name medication that is usually accompanied with a portion of patient cost-sharing, and that we observed patients with multiple prescription fills, we are reassured that the majority of patients with Acthar prescription claims actually received the medication. In addition, because this was an observational study and not a randomized control trial, we cannot be certain that the differences we observed between patients who were prescribed Acthar early versus later could not be explained by confounding factors. We attempted to correct for this by adjusting our models for potentially confounding variables, but unmeasured factors might play a role in the associations that we reported. Because we were interested in outcomes that occurred over the 12 months after the index IS diagnosis, we excluded patients who were not enrolled in their health plans for 1 year after the index event, so our population was stable by definition, and our results are likely not generalizable to more transient populations. We also did not have information on procedures or healthcare resource utilization for which patients paid out-of-pocket rather than filing claims through their insurance companies, and our cost estimates might, therefore, be conservative. Furthermore, the population of patients in the MarketScan databases is not randomly sampled and some populations, such as patients insured by small employers, were not represented in this study population. Therefore, these results may not be generalizable across all patients with IS in the US. Finally, we were unable to account for potential lag times from initial IS symptoms until definitive diagnoses were observed in the claims data. Patients who had been experiencing symptoms for substantial periods of time before their IS diagnosis may have been erroneously placed in the "early" treatment category, when in reality, their treatments could have been delayed if measured from the time that their symptoms first occurred. These unmeasured delays likely would have impacted healthcare utilization and costs for these patients.

Conclusions {#Sec8}
===========

In summary, we determined that earlier prescribing of Acthar to treat IS was associated with fewer outpatient procedures compared to later prescribing of this drug. Future studies should expand upon this descriptive work by focusing on analyzing long-term neurological outcomes both among patients who are prescribed Acthar early versus later, as well as examining outcomes among patients who are prescribed Acthar compared to other IS treatments.
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